Product Launch

     
BW20030501002139  20030502T060010Z UTC


( BW)(PALL-CORPORATION)(PLC) Product Launch

    Business Editors
    UK REGULATORY NEWS

    EAST HILLS, N.Y--(BUSINESS WIRE)--May 2, 2003--

    Pall Receives FDA Nod to Market Novel Blood Filtration System

Pall Corporation (NYSE:PLL) announced today that the Food and Drug
Administration (FDA) granted clearance to market its new Leukotrap
WB(R) Filtration System. This incorporates Pall's patented SAVE
technology, an automated blood recovery and air removal system that
enables maximum recovery of red blood cells and plasma.

It is the first whole blood collection, filtration and pre-storage
system that eliminates the need for "burping," the repetitive manual
manipulation required to express air from filtered whole blood. SAVE
stands for Sterile Air Venting Elimination.

After whole blood is collected, air is traditionally forced out of the
blood bag by burping -- manually squeezing-- the bag before the blood
undergoes additional processing prior to transfusion. Technicians can
squeeze as many as 60 bags per hour, one bag every minute. This is a
tedious and time-consuming task that has been associated with
repetitive strain injuries. The SAVE system automatically and reliably
removes the air, eliminating this manipulation step. The presence of
air can impede subsequent component processing and potentially
interfere with visual inspection.

"We anticipate rapid adoption of this new system because it is easy to
use, overcomes the problems associated with burping and provides the
assurance of maximum blood recovery without compromising filter
performance," said Roberto Perez, President of Pall Medical. "It also
provides rapid filtration times and consistently low levels of
residual leukocytes (white blood cells) in processed red cells and
plasma, giving customers the consistency and reliability they expect
from our filters."

The new system is also configured with the Pall Sample Diversion
Pouch, recently cleared for market by the FDA to divert the initial
volume of donor blood during collection, as part of a bacterial risk
management program. High levels of bacteria that can contaminate a
blood transfusion are generally found in the first blood drawn from
the venipuncture skin site of a blood donation.

"This unique combination of technologies provides blood centers a user
friendly way to enhance transfusion safety and efficiency," Mr. Perez
added. "This is one more addition to the Pall product line of next
generation leukoreduction systems to help ensure that transfused blood
is as safe as possible for all who need this life saving resource."

These new technologies are the latest in a spate of recent FDA
clearance to market for several new transfusion products from the
Company. These include the Pall BDS (bacterial detection system),
which tests platelets for the presence of bacteria, and the RC2D
Leukocyte Reduction Filter, which maximizes plasma recovery and
improves blood processing efficiency even under extreme processing
conditions.

The Leukotrap WB Filtration System with SAVE will be available to
blood centers within a few weeks.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of
filtration, separations and purification. Pall's business is organized
around two broad markets: Life Sciences and Industrial. The Company
provides leading-edge products to meet the demanding needs of
customers in biotechnology, pharmaceuticals, transfusion medicine,
semiconductors, municipal drinking water and aerospace. Total revenue
for Pall Corporation is $1.3 billion. The Company is headquartered in
East Hills, New York, and has operations in more than 30 countries.
Further information can be found on its web site at
http://www.pall.com.

   Short Name: Pall Corporation
   Category Code: PRL
   Sequence Number: 00004473
   Time of Receipt (offset from UTC): 20030501T190940+0100

    --30--BW/ny*  DB/ny

    CONTACT: Pall Corporation
             Media Inquiries:
             Roberto Perez, 516/801-9555
             [e-mail]
             or
             Investor Relations Inquiries:
             Diane Foster, 516/801-9848
             [e-mail]

    KEYWORD: NEW YORK UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES MEDICAL
GOVERNMENT PRODUCT
    SOURCE: Pall Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com